middle.news
Why CSL’s 14% Profit Surge Signals a New Era with Seqirus Demerger
7:48am on Tuesday 19th of August, 2025 AEST
•
Healthcare
Read Story
Why CSL’s 14% Profit Surge Signals a New Era with Seqirus Demerger
7:48am on Tuesday 19th of August, 2025 AEST
Key Points
Revenue up 5% to US$15.558 billion
Net profit after tax rises 14% to US$3.002 billion
Launch of Andembry for hereditary angioedema
Plan to demerge CSL Seqirus vaccines business
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CSL (ASX:CSL)
OPEN ARTICLE